A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Ofatumumab (Primary) ; Alemtuzumab; Methylprednisolone
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 06 May 2016 Status changed from active, no longer recruiting to recruiting.
- 08 Dec 2015 Interim results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.